Auscann Group Holdings Ltd
ASX:AC8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Auscann Group Holdings Ltd
ASX:AC8
|
AU |
|
Midland Exploration Inc
XTSX:MD
|
CA |
|
Union Bank of India Ltd
NSE:UNIONBANK
|
IN |
|
Shenzhen Fluence Technology PLC
SZSE:300647
|
CN |
|
R
|
Reliance Infrastructure Ltd
BSE:500390
|
IN |
|
GYP Properties Ltd
SGX:AWS
|
SG |
|
W
|
Woolworths Holdings Ltd
JSE:WHL
|
ZA |
|
C
|
CSSC Offshore & Marine Engineering Group Co Ltd
HKEX:317
|
CN |
|
Verditek PLC
LSE:VDTK
|
UK |
|
Energem Corp
NASDAQ:GTI
|
MY |
|
I
|
IberAmerican Lithium Corp
OTC:IBRLF
|
CA |
|
N
|
Neuca SA
WSE:NEU
|
PL |
|
T
|
Tianjin Binhai Teda Logistics Group Corp Ltd
HKEX:8348
|
CN |
|
F
|
First International Bank of Israel Ltd
TASE:FIBI
|
IL |
|
Hindustan Unilever Ltd
NSE:HINDUNILVR
|
IN |
|
N
|
Nanjing Toua Hardware&Tools Co Ltd
SZSE:301125
|
CN |
|
Kuniko Ltd
ASX:KNI
|
AU |
|
Gome Telecom Equipment Co Ltd
SSE:600898
|
CN |
|
F
|
Falck Renewables SpA
LSE:0NXV
|
IT |
|
C
|
CDRL SA
WSE:CDL
|
PL |
|
J
|
JK Tyre & Industries Ltd
BSE:530007
|
IN |
|
A
|
Altri SGPS SA
ELI:ALTR
|
PT |
|
Graham Holdings Co
NYSE:GHC
|
US |
|
A
|
Attica Holdings SA
ATHEX:ATTICA
|
GR |
Auscann Group Holdings Ltd
AusCann Group Holdings Ltd. engages in development, production, and distribution of cannabinoid-based medicines within Australia and internationally. The company is headquartered in Perth, Western Australia. The firm focuses on providing healthcare professionals and veterinarians with pharmaceutical and nutraceutical products to support the treatment of their patients. Its controlled-dose technology platform, Neuvis, is for delivering cannabinoids to human patients through CannPal Animal Therapeutics Pty Ltd. DermaCann is its lead cannabidiol (CBD) derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. CPAT-01 is a liquid, oral veterinary medicine containing tetrahydrocannabinol (THC) and CBD whole plant extracts in a combined ratio to cure pain and inflammation in dogs. CPAT-01 is in Phase II clinical trials. AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited are its subsidiaries.
AusCann Group Holdings Ltd. engages in development, production, and distribution of cannabinoid-based medicines within Australia and internationally. The company is headquartered in Perth, Western Australia. The firm focuses on providing healthcare professionals and veterinarians with pharmaceutical and nutraceutical products to support the treatment of their patients. Its controlled-dose technology platform, Neuvis, is for delivering cannabinoids to human patients through CannPal Animal Therapeutics Pty Ltd. DermaCann is its lead cannabidiol (CBD) derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. CPAT-01 is a liquid, oral veterinary medicine containing tetrahydrocannabinol (THC) and CBD whole plant extracts in a combined ratio to cure pain and inflammation in dogs. CPAT-01 is in Phase II clinical trials. AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited are its subsidiaries.
